Evaluation and management of steroid-unresponsive nephrotic syndrome

Current Opinion in Pediatrics

Volumn 20, Issue 2, 2008, Pages 151-156

  Del Rio, Marcela ^a   Kaskel, Frederick ^a  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Focal segmental glomerulosclerosis; Nephrotic syndrome; Steroid resistant nephrotic syndrome; Steroid sensitive nephrotic syndrome

Indexed keywords

ALKYLATING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; IMMUNOSUPPRESSIVE AGENT; LISINOPRIL; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PLACEBO; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; HUMAN; INCIDENCE; KIDNEY INJURY; LOW DRUG DOSE; MONOTHERAPY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHILD; CYCLOSPORINS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 40549137748     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f4e6e4     Document Type: Review

References (59)

1. ISKDC. International Study of Kidney Disease in Children: Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 1978; 13:159-165.
2. Churg J, Habib R, White RHR. Pathology of the nephrotic syndrome in children. Lancet 1970; 1:1299-1302.
3. Chesney R. The changing face of childhood nephrotic syndrome. Nephrology forum. Kidney Int 2004; 66:1294-1302.
4. Boyer O, Moulder JK, Somers MJ. Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol 2007; 22:1159-1166. A similar review of the data shows increasing incidence of SRNS secondary to FSGS.
5. Fernandes Borges F, Shiraichi L, Da Silva MP, et al. Is focal segmental glomerulosclerosis increasing in patients with nephrotic syndrome? Pediatr Nephrol 2007; 22:1309-1313. This reviews data regarding increasing incidence of FSGS up to the current time.
6. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362:629-639 [seminar].
7. Hogg R, Middleton J, Vehaskari VM. Focal segmental glomerulosclerosis- epidemiology aspects in children and adults. Pediatr Nephrol 2007; 22:183-186. This article provides an overview of the epidemiology of FSGS by reviewing published surveys of renal biopsies, experiences from clinical registries of children with renal insufficiency, and data from the US Renal Data Systems.
8. Trachtman H. Educational feature on focal segmental glomerulosclerosis: an introduction. Pediatr Nephrol 2007; 22:26-27. This commentary introduces a series of educational articles covering the epidemiology, pathophysiology, genetics and treatment of SRNS secondary to FSGS.
9. North American Renal Trials and Collaborative Studies (NAPRTCS). 2006 Annual Report. Boston: NAPRTCS administrative office; 2006. This is a comprehensive database on the epidemiology and treatments for kidney failure in children in North America.
10. Chua AN, Alexander SR, Sarwal MM, et al. Proteinuria in pediatric renal transplant recipients during the first 60 posttransplant days. Pediatr Transplant 2006; 10:957-961. The authors refresh our memory regarding the risk for recurrence of original disease posttransplant.
11. Reidy K, Kaskel F. Pathophysiology of focal segmental glomerulosclerosis. Pediatr Nephrol 2007; 22:350-354. This article reviews some of the experimental and clinical data on the pathophysiology of progression in FSGS and emphasizes the mechanisms of podocyte injury in various models.
12. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:117-134.
13. D'Agati VD, Fogo AB, Brujin JA. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004; 368-382.
14. Albaqumi M, Soos TJ, Barisoni L, Nelson PJ. Collapsing glomerulopathy. J Am Soc Nephrol 2006; 17:2854-2863. This is a complete description of the histologic entity of collapsing FSGS.
15. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69:920-926. This is a thorough evaluation of the different histologic subtypes in FSGS, their clinical characteristics, response to therapies and outcome and progression.
16. El-Refaey AM, Kapur G, Jain A, et al. Idiopathic collapsing focal segmental sclerosis in pediatric patients. Pediatr Nephrol 2007; 22:396-402. This original article from the Children's Hospital of Michigan describes their experience with both collapsing and noncollapsing FSGS. Surprisingly, only one patient with the former diagnosis progressed. Effective treatment prevented progression in this high-risk group.
17. Silverstein DM, Craver R. Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:700-707. An original article from the Children's Hospital, New Orleans, describes their experience with the variants of FSGS and outcome, demonstrating that there was no difference between African-Americans and Caucasians.
18. Gipson DS, Chin H, Presler T, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 2006; 21:344-349. This is a review of their experience with FSGS based upon response to therapies. Remission of proteinuria had best outcome.
19. Khurana M, Traum AZ, Aivado A, et al. Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol 2006; 21:1257-1265. This is an original article from the Children's Hospital, Boston.
20. Woroniecki RP, Shatat IF, Supe K, et al. Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood. Am J Nephrol 2008; 28:83-90. An original report evaluates the urinary cytokine profile in relation to response to treatment in INS.
21. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354:1387-1401. This is an excellent review on the normal glomerular filtration barrier and mechanisms of disease.
22. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. In depth review. Clin J Am Soc Nephrol 2007; 2:529-542. This discusses a proposed new and interesting taxonomy based on the histopathology and etiology of glomerular diseases associated with podocyte injury.
23. Gubler MC. Podocyte and hereditary nephrotic syndromes. World J Pediatrics 2007; 3:8-16. The authors describe the role of podocyte pathophysiology in genetic disorders in nephrotic syndrome.
24. Woroniecki RP, Kopp JB. Genetics of focal segmental glomerulosclerosis. Pediatr Nephrol 2007; 22:638-644. This reviews recent advances in newly discovered genes and proteins affecting the glomerular filtration barrier and FSGS with indications for future therapies.
25. Schwab K, Witte DP, Aronow BJ, Devarajan P, et al. Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol 2004; 24:438-447.
26. Shatat IF, Schoeneman M, Flynn JT, Woroniecki RP. Association of steroid and cyclosporine resistance in focal segmental glomerulosclerosis. Pediatr Nephrol 2007; 22:834-839. An original report describes the association of steroid resistance to subsequent CsA resistance and the need to screen for potential genetic mutations in SRNS patients before administering additional immunosuppression.
27. Gipson DS, Gibson K, Gipson PE, et al. Therapeutic approach to FSGS in children. Pediatr Nephrol 2007; 22:28-36. This educational article reviews the current therapeutic approach including non-immunological, conventional and experimental treatments in children with primary FSGS. Excellent review.
28. Appel GB, Waldman M, Radhakrishnan J. New approaches to the treatment of glomerular diseases. Kidney Int 2006; 70:545-550. This concise article reviews newer selective immunomodulating and immunosuppressive regimens, including MMF, rituximab, sirolimus, calcineurin inhibitors, and eculizumab, in adults with different etiologies for SRNS.
29. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1:1054-1065. This is an excellent review of the experimental and clinical literature important in understanding the physiologic rationale for interference with the renin-angiotensin system in proteinuric diseases.
30. Wühl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004; 66:768-776.
31. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:45-50.
32. Tune BM, Kirpekar R, Sibley RK, et al. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995; 43:84-88.
33. Nammalwar BR, Vijayakumar M, Prahlad N, Jain DV. Steroid resistant nephrotic syndrome: Is sustained remission attainable? Indian Pediatr 2006; 43:39-43. This is a review of their experience with intravenous pulse methylprednisolone and cyclophosphamide and oral prednisone in SRNS. A good response was found in MCD patients although increased risk for infections was observed.
34. Peňa A, Bravo J, Melgosa M, et al. Steroid-resistant nephrotic syndrome: long-termevolution after sequential therapy. Pediatr Nephrol 2007; 22:1875-1880. A single-center report on their positive experience with sequential therapy in MCD and FSGS adds support for the use of a modified Mendoza/Tune protocol in SRNS.
35. Chang JW, Yang LY, Wang HH. Low-dose methylprednisolone pulse therapy in Chinese children with steroid resistant focal segmental glomerulosclerosis. Pediatr Int 2007; 49:349-354. This is a single-center report on the efficacy of low-dose pulse steroids in SRNS secondary to FSGS, again adding renewed interest in the original reports by Mendoza/Tune.
36. Drube J, Geerlings C, Taylor R, et al. Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine-A. Pediatr Nephrol 2007; 22:600-602. A case report demonstrates the efficacy of CsA to induce a remission long after steroids and cyclophosphamide failed.
37. Zietse R, Wenting GJ, Kramer P, et al. Effects of cyclosporine A on glomerular barrier function in the nephrotic syndrome. Clin Sci 1992; 82:641-650.
38. Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicenter randomized controlled trial. Nephrol Dial Transplant 1993; 8:1326-1332.
39. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in childen. J Am Soc Nephrol 1996; 7:56-63.
40. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56:2220-2226.
41. El-Husseini A, El-Basuony F, Mahmoud I, et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-center experience. Nephrol Dial Transplant 2005; 20:2433-2438.
42. Iyengar A, Karthik S, Kumar A, et al. Cyclosporine in steroid dependent and resistant nephrotic syndrome. Indian Pediatr 2006; 43:14-19. The authors evaluated CsA monotherapy in SRNS and dependent children. There was a good response rate but many became CsA-dependent, especially if younger.
43. Bagga A. Steroid resistant nephrotic syndrome: Recent Developments. Indian Pediatr 2006; 43:9-13. This reviews advances in the field from Indian investigations and makes a case for randomized controlled clinical trials.
44. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007; 26 Sept [Epub ahead of print]. This review provides the evidence for the use of CsA in inducing remission in MCD and SRNS secondary to FSGS and provides algorithms for evaluation and treatment in adult and pediatric patients. It offers a useful guide to cyclosporine in renal disease.
45. Colquitt JL, Kirby J, Green C, et al. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol Assess 2007; 11:1-93. This review assessed the clinical and cost-effectiveness of treatments for children with idiopathic SRNS. Eleven trials were examined and evidence supported the efficacy of CsA in inducing remissions in the non-FSGS group and for the effectiveness of cyclophosphamide on time for remission. It emphasizes the need for a modeling framework for a well designed RCT comparing CsA with other treatments in children with SRNS without genetic mutations.
46. Hodson EM, Habashy D, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2007; (2):CD003594. This review evaluates the benefits and harm of 11 different randomized and quasi-randomized controlled trials used in 213 children with idiopathic nephrotic syndrome who did not achieve remission following four weeks or more of daily corticosteroid therapy. It supports the efficacy of CsA in inducing remission and the use of ACEI in reducing proteinuria but emphasizes the need for well designed RCTs to confirm the efficacy of CsA and to evaluate other regimens for idiopathic SRNS.
47. Choi MJ, Eustace JA, Gimenez LF. Mycophenolate mofetil treatment for primary glomerular disease. Kidney Int 2002; 61:1098-1114.
48. Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:405-411.
49. Montane B, Abitbol C, Chandar J, et al. Novel therapy of focal segmental glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18:772-777.
50. Hogg RJ, Fitzgibbons L, Bruick J, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: A recent report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:1173-1178. This multicenter investigation found MMF to be safe and effective in maintaining remission in steroid-responsive but frequently relapsing patients.
51. Fujinaga S, Ohtomo Y, Umino D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:71-76. A recent update demonstrates the efficacy of MMF in reducing the dose of CsA and prednisolone in patients with steroid-dependent nephrotic syndrome.
52. Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of Sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006; 1:109-116. This report describes the reduction in proteinuria and glomerular pore size and increase in glomerular ultrafiltration coefficient by Sirolimus in patients with SRNS secondary to FSGS.
53. Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute Rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19:1288-1292.
54. Loeffler K, Gowrishankar M, Yiu V. Tacrolimustherapy in patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:281-287.
55. Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 2006; 26:544-551. This is another report on the effectiveness of tacrolimus in inducing remission in FSGS patients.
56. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:906-913. The authors describe the first experience with this antifibrotic agent used to prevent progression in adults and make a case for additional studies.
57. Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 2007; 22:892-898. This reviews the current field of knowledge regarding this new therapy and sets the template for future randomized controlled studies.
58. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354:1961-1963. This is one of the first reports on the experience with rituximab in recurrent FSGS.
59. Middleton J, Thomas DB, Kaskel FJ, et al. Focal segmental glomerulosclerosis: the need for improved treatment options and the basis for the ongoing NIH clinical trial. Nephrology Rounds 2007; 5:1-6. The authors review the histology, genetics, and current treatments for FSGS and the design of the NIH FSGS-CT that will evaluate possible treatment modalities.